Treace Medical Concepts, Inc.

NASDAQ:TMCI

Medical - Devices

Healthcare
$4.53 +1.87%

+$0.08 today

Market cap
$296.98M
Beta
1.41
P/E (TTM)
-4.3
EPS (TTM)
-$0.95
52W Low $1.17High $7.78

Volume 0.18M

Average 0.73M

TMCI Pre-Tax Margin

Income before tax as a percentage of revenue.

Treace Medical Concepts, Inc.NASDAQ: TMCI

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -38.1%

Pre-tax margin was -38.1% in Q1 FY2026, down 7.8 pp from a year earlier. On a trailing-twelve-month basis it was -29.4%, down 4.3 pp year over year. Over 3 fiscal years it widened by 2.4 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-38.1%-23.0 pp QoQ
Last fiscal yearDec 2025
-27.7%-1.1 pp YoY
LTMMar 2026
-29.4%-4.3 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.8 pp——
1 year-1.1 pp——
3 years+2.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-27.7%
Year-over-year change
-1.1pp

Pre-Tax Margin vs competitors

How TMCI compares with its peers on the latest reported figures

  • TMCI's LTM Mar 2026 pre-tax margin of -29.4% is the 5th highest of the 8 companies compared; the peer median is -16.3%.
  • Its year-over-year change of -4.3 pp is the 6th highest of 8, against a peer median of +3.5 pp.
  • Over three fiscal years its change of +2.4 pp compares with a peer median of +41.4 pp.
TMCI Competitors Peer median
Pre-Tax Margin for TMCI and competitors
Company Period LTM level YoY 3-year change
BVSBioventus Inc.LTM Mar 20265.8% +14.6 pp+41.4 pp
TOIThe Oncology Institute, Inc.LTM Mar 2026-8.0% +8.0 pp-12.0 pp
EOLSEvolus, Inc.LTM Mar 2026-14.1% +6.0 pp+32.9 pp
KIDSOrthoPediatrics Corp.LTM Mar 2026-16.3% +3.5 pp-13.6 pp
TMCITreace Medical Concepts, Inc.LTM Mar 2026-29.4% -4.3 pp+2.4 pp
RXSTRxSight, Inc.LTM Mar 2026-36.5% -19.8 pp+107.3 pp
CBLLCeriBell, Inc.LTM Mar 2026-63.5% -0.9 pp+83.4 pp
LABStandard BioTools Inc.LTM Mar 2026-101.8% -20.3 pp+83.6 pp
Peer median (excluding TMCI) -16.3%+3.5 pp+41.4 pp

Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.42M141.84M187.12M209.36M212.69M
Cost of Revenue16.89M27.52M35.18M41.09M42.94M
Gross Profit77.53M114.32M151.94M168.26M169.75M
Gross Margin82.1%80.6%81.2%80.4%79.8%
Research & Development10.2M13.58M15.44M20.59M20.28M
Selling, General & Admin83.84M137.57M187.93M203.36M203.62M
Operating Expenses94.04M149.16M203.37M223.95M223.91M
Depreciation & Amortization685K2.13M5.35M8.42M10.5M
EBITDA(15.81M)(36.28M)(39.01M)(42.07M)(43.18M)
EBITDA Margin-16.7%-25.6%-20.8%-20.1%-20.3%
Operating Income(16.51M)(34.84M)(51.43M)(55.69M)(54.15M)
Operating Margin-17.5%-24.6%-27.5%-26.6%-25.5%
Interest Income18K1.31M6.73M4.88M2.78M
Interest Expense4.06M4.4M5.17M5.26M5.32M
Other Income / Expenses(4.04M)(7.97M)1.9M(55K)(4.85M)
Income Before Tax(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Pre-Tax Margin-21.8%-30.2%-26.5%-26.6%-27.7%
Income Tax Expense00000
Net Income(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Net Margin-21.8%-30.2%-26.5%-26.6%-27.7%
EPS (Basic)(0.38)(0.77)(0.81)(0.90)(0.93)
EPS (Diluted)(0.38)(0.77)(0.81)(0.90)(0.93)
Weighted Avg Shares54.18M55.28M60.85M62.11M63.27M
Weighted Avg Shares (Diluted)54.18M55.28M60.85M62.11M63.27M

Treace Medical Concepts, Inc.

NASDAQ:TMCI

Intrinsic Alpha fair value

Locked

Current Price

$4.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.